Hong Kong – Artificial intelligence is a growing presence in biopharma, with applications beyond the discovery apparatus. It was a hot-button issue in San Francisco last week as the industry gathered around the annual JP Morgan Healthcare Conference. Eli Lilly and Novartis even announced multi-million-dollar discovery deals with Alphabet’s Isomorphic...
treatment News
Rockville, Maryland – Insilico Medicine, a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class poly hydroxylase domain (PHD) 1/2 inhibitor for the treatment of inflammatory bowel disease (IBD). Designed and developed by Insilico’s proprietary end-to-end AI...
Hong Kong – Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, recently published an early research that it has identified MYT1 as a promising new therapeutic target for breast and gynecological cancer, and discovered a series of novel, potent, and highly selective inhibitors specifically targeting MYT1....
CAMBRIDGE, Mass. — Insilico Medicine, a clinical-stage generative AI-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings...
Cambridge, MA, Sept 18, 2024 – Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis...
BRIDGEWATER, N.J — Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of...
JUPITER, Fla. — Like the Greek mythological beast with a snake’s tail and two ferocious heads, a potential Parkinson’s medicine created in the lab of chemist Matthew Disney, Ph.D., is also a type of chimera bearing two heads. One seeks out a key piece of Parkinson’s-causing RNA, while the other...
NEW YORK, NY — Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today a licensing agreement with Merck KGaA, Darmstadt, Germany for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, currently in development for RAS mutated (RASm) second-line (2L) advanced or metastatic...
SAN DIEGO, Calif. – TG4050, a personalized neoantigen vaccine, induced tumor-specific immune responses and led to low rates of disease relapse in patients with surgically resected HPV-negative head and neck squamous cell cancer (HNSCC), according to results reported at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-1...
AHMEDABAD, India – One of India’s leading pharmaceutical companies, Intas Pharmaceuticals, takes a revolutionary step towards making therapy for Acute Myeloid Leukemia (a type of blood cancer) more accessible to patients by being the first to launch Oral Azacitidine in India under the brand name of Azadine-O. Oral Azacitidine is approved for use in maintenance...